Title: Human-level information extraction from clinical reports with fine-tuned language models

Authors: Longchao Liu, BA [1]*, Long Lian, BA [1]*, Yiyan Hao, BS [2], Aidan Pace, BE[3], Elaine Kim, BS[3], Nour Homsi, BS[4], Yash Pershad, BS [5], Liheng Lai[1], Thomas Gracie, MD [6], Ashwin Kishtagari, MD [7], Peter R Carroll, MD, MPH [8], Alexander G Bick MD, PhD [5], Anobel Y Odisho, MD, MPH[8,9], Maggie Chung, MD[10]^, Adam Yala, PhD[1,9,11]^

1. Electrical Engineering and Computer Sciences, UC Berkeley, 387 Soda Hall, Berkeley, CA 94720
2. Department of Bioengineering, University of Pennsylvania, 210 South 33rd St, Philadelphia, PA 19104
3. University of California San Francisco School of Medicine, 533 Parnassus Ave, San Francisco, CA 94143.
4. University of California Riverside School of Medicine, 92521 Botanic Gardens Dr, Riverside, CA 92507
5. Division of Genetic Medicine, Department of Medicine, Vanderbilt University Medical Center, 2213 Garland Avenue, Nashville, TN 37232
6. Department of Medicine, Vanderbilt University Medical Center, 2213 Garland Avenue, Nashville, TN 37232
7. Vanderbilt Ingram Cancer Center, Vanderbilt University Medical Center, 2220 Pierce Ave, Nashville, TN 37232
8. Department of Urology, School of Medicine, University of California San Francisco (UCSF), 1825 4th St, Box 1695, San Francisco, CA 94143
9. Computational Precision Health, UC Berkeley and UCSF, 2177 Hearst Ave, Berkeley, CA 94709
10. Department of Radiology and Biomedical Imaging, School of Medicine, University of California San Francisco (UCSF), 505 Parnassus Ave, San Francisco, CA 94143.
11. Department of Statistics, UC Berkeley, 367 Evans Hall, Berkeley, CA 94720

Joint first authors
^ Joint senior authors

Corresponding author:
Adam Yala PhD
Email: yala@berkeley.edu, Phone: 224-465-7241
Address: 2177 Hearst Ave, Berkeley, CA 94709

Funding information:

AY is supported by the E.P. Evans Foundation and Breast Cancer Research Foundation awards. AGB is supported by NIH grants DP5 OD029586, a Burroughs Wellcome Fund Career

Award for Medical Scientists, the E.P. Evans Foundation, and a Pew-Stewart Scholar for Cancer Research award, supported by the Pew Charitable Trusts and the Alexander and Margaret Stewart Trust. MC is supported by the Radiological Society of North America Research Scholar Grant. Funders did not directly influence or partake in this study.

Manuscript type: Original Research

Word Count for Text: 2997

Data sharing statement: We release Strata, our LLM-based library, as an open-source tool on GitHub. Strata supported all experiments reported in this study. The clinical reports used in this study contain protected health information and cannot be shared due to patient privacy concerns.

Title:
Human-level information extraction from clinical reports with fine-tuned language models

Article Type:
Original Research

Summary Statement

Fine-tuned open-source LLMs achieved human-level performance in extracting structured outcomes from prostate MRI, breast pathology, kidney pathology, and myelodysplastic syndrome pathology reports, supporting diverse research applications.

Key Results

- Fine-tuned Llama-3.1 8B obtained human-level exact match accuracies in all four test sets.
- 100, 95, 43, and 72 training reports from the breast pathology, kidney pathology, prostate MRI, and myelodysplastic syndrome pathology datasets were needed for fine-tuned Lamma-3.1 8B to achieve human-level performance.
- Each fine-tuned model required 1-3 hours of training on a single A40 GPU, costing between $0.80 to $2.40 on a private cloud.

Abbreviations:
LLM: large language model
MDS: Myelodysplastic syndrome
MRI: Magnetic resonance imaging

Abstract

Background: Extracting structured data from clinical notes is a key bottleneck in developing AI tools for radiology and pathology. Manual annotation is labor-intensive and unscalable. An efficient, automated method for clinical information extraction with human-level performance is urgently needed.

Purpose: To introduce a low-code open-source library, [Strata](#), that facilitates fine-tuning, evaluating, and deploying large language models (LLMs) for structured data extraction from clinical reports.

Materials and Methods: Four clinical datasets were annotated by a trained human annotator: 431 prostate MRI reports, 978 breast pathology reports, 238 kidney pathology reports, and 724 myelodysplastic syndrome (MDS) pathology reports. Datasets were split into training, development, and test sets. A second reader annotated the test set. We fine-tuned open-source LLMs (Llama-3.1 8B, Mistral-v0.3 7B) to extract variables from clinical reports. We evaluated zero-shot and fine-tuned open-source models, zero-shot GPT-4, and the second human annotator using exact match accuracy. Exact match accuracy assesses if all variables for a report were extracted correctly.

Results: The second human annotator obtained exact match accuracies of 83.1 (95% CI 75.4, 88.5), 75.5 (95% CI 70.4, 80.3), 70.8 (95% CI 59.7, 80.6), and 85.8 (95% CI 80.7, 89.9) in the prostate, breast, kidney, and MDS test sets, respectively. Our fine-tuned Llama-3.1 8B model achieved human-level performance across all fine-tuning settings with exact-match test-set accuracies of 91.5 (95% CI 85.4, 95.4), 91.5 (95% CI 88.1, 94.2), 72.2 (95% CI 61.1, 81.9), and 89.4 (95% CI 84.9, 93.1) for prostate, breast, kidney, and MDS reports, respectively. We found that ≤ 100 training reports were needed to achieve human-level performance on these tasks.

Conclusion: Strata enables automated human-level performance in extracting structured data from clinical notes using ≤ 100 training reports.

Main Body (3000 words)

Introduction

Artificial intelligence (AI) tools in radiology and pathology hold great potential to improve patient care by learning patterns across massive, well-annotated datasets. These datasets pair medical images with reference standard labels derived from clinical notes, such as pathology and radiology reports. For example, image-based risk models in breast cancer have leveraged hundreds of thousands of mammograms paired with pathologic cancer outcomes derived from tens of thousands of pathology reports (1). While images are readily available for research use, extracting ground-truth labels from clinical notes remains a critical research bottleneck. The traditional approach to label curation is manual chart review, where researchers annotate thousands of reports. If the team wishes to add a new variable to their research database, a new round of exhaustive annotation is required. It is intractable to create health-system scale datasets with retrospective manual annotation, limiting clinical research. There remains a critical unmet need for automated data extraction from clinical reports with human-level performance.

Automated tools, including deep learning (2,3), statistical machine learning (4–7), and rule-based (20–22) methods, have been proposed to extract structured information from clinical reports. While these systems have achieved promising performance, they require substantial effort to develop and deploy. As a result, their adoption by the research community remains limited. Large language models (LLMs) have demonstrated exciting capabilities in general text understanding, detecting errors in radiology reports (8), streamlining radiology report impressions (9,10), and automatic synoptic reports (11). Despite the promising capabilities of commercial LLMs, they are ill-suited for large-scale research database curation due to reproducibility, cost, and privacy concerns. Commercial LLMs are continually updated, and a new version of the LLM may unexpectedly perform worse when given the same inputs; it is infeasible to reproduce prior extractions after model updates. Furthermore, costs associated with using commercial LLM can pose significant barriers, and institutional agreements are often required to address privacy concerns. Ideally, researchers could locally host their LLMs ("self-hosting"); these local LLMs would enable rigorous reproducible research practices while minimizing costs and avoiding the transfer of sensitive data.

Open-source LLMs, such as Llama (12–14) and Mistral (15), offer a promising solution for efficient "self-hosted" information extraction. They demonstrate similar general text understanding capabilities to commercial tools (e.g., ChatGPT) while enabling flexible customization and self-hosting. We hypothesize that with limited computing expense (i.e., a few hours on a single GPU) and a limited annotation budget (i.e., <100 reports),

open-source LLMs could achieve human-level performance in extracting information from clinical reports. This study aims to rigorously explore the customization of open-source LLMs for clinical information extraction, performing experiments across real-world research databases from prostate magnetic resonance imaging (MRI) reports and breast, kidney, and bone marrow pathology reports. Across each setting, we compare the performance of open-source LLMs with their fine-tuned variants, zero-shot GPT-4, and a second human annotator. To facilitate the broader adoption of customized open-source LLMs, we release a low-code open-source library, Strata, to support the fine-tuning, evaluation, and deployment of LLMs for clinical information extraction.

Materials and Methods

The local institutional review board approved this Health Insurance Portability and Accountability Act-compliant study and waived the requirement for written informed consent. We collected four diverse clinical text datasets underlying active research projects at our institutions across breast, kidney, prostate, and bone marrow cancer (Myelodysplastic Syndrome, MDS). These real-world datasets represent our intended use cases, where LLM-based tools empower the automatic creation of large-scale structured datasets. Our breast, kidney, and prostate datasets were annotated by a research assistant, and our MDS dataset was annotated by a hematologist. We describe each dataset in detail, including its creation and annotation process, in our supplementary methods.

Extracting Structured Information using Customized Large Language Models

State-of-the-art LLMs are trained to follow instructions specified in text prompts when generating their answers. This process, called instruction-tuning (16), enables users to define tasks with instruction prompts. To leverage instruction-tuned LLMs for clinical information extraction, a user can write out the desired task (e.g., extract the cancer subtype from a pathology report) in a text prompt before inputting the full clinical report. Given the prompt and the clinical report, the LLM will generate an answer in the text format, which can be parsed into the desired structured format using a simple post-processing script. This process is illustrated in Figure 2.

In this work, we are interested in customizing LLMs for clinical information extraction. To enable the full research community to benefit from this resource, we focus on LLMs that can be easily hosted on a single consumer desktop-grade GPU, such as the Nvidia RTX 3090 or 4090. As a result, we leverage relatively small LLMs: Llama-3.1 8B and Mistral-v0.3 7B. These billion-parameter LLMs are orders of magnitude smaller than state-of-the-art LLMs such as Llama-3.1 405B and GPT-4. To enable smaller LLMs to achieve human-level performance in clinical information extraction, we fine-tune them. Specifically, we leverage simple preprocessing scripts to convert human-annotated

structured labels (i.e., in a tabular format) to text answers for the LLM to generate (e.g., "My answer is: {"DCIS": "yes", "ILC": "no"}"). Given a dataset of pairs of clinical reports and answer texts, we can train the LLM to correctly predict the intended answer from the user prompt and clinical report. This process is illustrated in Figure 3. To fine-tune LLMs using small local hardware, we employ Low-Rank Adaption (LoRA) (17). Instead of directly optimizing the billions of parameters in our LLMs, LoRA keeps the initial weights of the LLM frozen and adds a small number of new parameters (e.g., <400M parameters) across the LLM to customize the model's behavior.

To enable the broader clinical and research communities to fine-tune and deploy their LLMs on local hardware, we developed Strata, a lightweight open-source library for clinical information extraction. As illustrated in Figure 3, Strata is used in three phases. First, researchers annotate a small dataset of clinical reports with their desired structured labels, which are partitioned into a training, development, and testing set. In addition to these annotations, researchers define the task for the LLM by specifying a prompt, a parsing script, and a template function. As described above, the parsing script maps the LLM's answer to the desired structured format, and the template function maps the structured annotation to a text-based answer. Given an annotated dataset, Strata supports LoRA-based fine-tuning and flexible hyperparameter optimization. Finally, Strata offers a rich automated evaluation suite for model selection. We leverage Strata across all our experiments.

LLM Development and Evaluation
Across all datasets, we developed prompts, parsing scripts, and template functions to maximize the performance of our open-source LLMs, Llama-3.1 8B and Mistral-v0.3 7B, on the development sets. In these experiments, Llama-3.1 and Mistral-v0.3 were used without fine-tuning (i.e. zero-shot). Given a final set of prompts and scripts, we fine-tuned Llama-3.1 and Mistral-v0.3 using LoRA on our training sets. We considered three possible variants of LLM fine-tuning. First, we trained a customized LLM for each task within each dataset separately (i.e., question-specific fine-tuning). Next, we explored dataset-specific fine-tuning, in which all tasks within a single dataset (e.g., specimen site, cancer presence, and subtyping) were included in fine-tuning a model. Finally, we also considered training a single fine-tuned LLM across all datasets and tasks (i.e., mixed-dataset fine-tuning). We describe our fine-tuning hyper-parameters in our supplementary methods.

We leverage the annotations of our first human annotator as our "ground truth" in all evaluations. Our primary evaluation metric is "exact-match accuracy," where we evaluate the ability of the LLM to extract all components of user-specified queries correctly. For instance, if the ground truth (i.e., first human annotator) response for breast cancer subtyping were "{DCIS: Yes, ILC: No, IDC: Yes}," the LLM predictions

would have to match across all fields to gain a point in our cancer subtyping exact-match accuracy calculation. For dataset-level exact match accuracies, the LLM must correctly extract the information across all user queries for that clinical report. In addition to our stringent exact match accuracies, we also evaluate macro-F1, precision, and recall scores in our supplementary analyses.

To contextualize our results, we compare our fine-tuned LLMs, Llama-3.1 and Mistral-v0.3, with their non-fine-tuned "zero-shot" variants. We also compare our results to GPT-4 and a second human annotator. All LLMs and the second human annotator were given the same prompts, and their extractions were compared to the first human annotator extractions as ground truth, using the metrics described above. The accuracy of our second human annotator serves as our benchmark for "human-level performance". We hypothesize that fine-tuned LLMs would be non-inferior to the second human annotator in clinical information extraction. Our goal is not to outperform the second human annotator in matching the first human annotator, as both annotations are valid; we expect disagreements between human annotators to reflect ambiguity in clinical reports. The second human annotator for each test set was a research assistant who received training on the relevant pathology classifications and the specific criteria for annotation for each dataset.

To understand the dependence of fine-tuned LLM performance on labeled data, we performed learning curve analyses. We randomly sampled subsets of each training set (consisting of 25% and 50% of the full training data) and fine-tuned using only the subsets at the dataset-specific level. We then evaluated the model performance with different subsets against the second human annotator to determine the number of labeled reports needed for human-level performance. To understand the effect of hyper-parameters on our performance, we performed a sensitivity analysis. For each hyperparameter (i.e., LoRA rank, LoRA scaling, number of epochs, and learning rate), we varied one hyperparameter value while holding the others constant and evaluated the difference in exact match accuracy.

Statistical Analysis
We used scikit-learn (version 1.5.1; *scikit-learn.org*) and SciPy (version 1.14.1; *scipy.org*) to compute all evaluation metrics, including F1-score, precision, and recall. We computed evaluation metrics across 5000 bootstrap samples (16) to obtain 95% confidence intervals (CIs). To compare the exact match accuracy of LLMs to the accuracy of a second human annotator, we utilized a non-inferiority t-test using the stats R package (version 4.4.1; *cran.r-project.org*). Given the size of each test set, 80% desired power, a 0.05 p-value, and the standard deviation of the second human annotator accuracy, we computed the margin of error measurable by each test set. This

power calculation was performed using the pwr R package (version 1.3-0; *cran.r-project.org*), and we utilized dataset-specific margins in each non-inferiority calculation. Given 294, 130, 72, and 218 reports in the breast, prostate, kidney, and MDS test sets, this resulted in non-inferiority margins of 6.3%, 8.2%, 13.5%, and 5.9%, respectively.

Results

Report Characteristics

Our breast, kidney, prostate, and MDS datasets contained 978, 238, 431, and 724 reports (Figure 1). Of these reports, 294, 72, 130, and 218 were randomly selected for held-out testing for breast, kidney, prostate, and MDS extractions, and these reports contained an average of 766, 688, 423, and 785 words, respectively. Amongst breast, kidney, and prostate test sets, 65%, 94%, 85% contained a confirmation of cancer. 7% of the MDS test set confirmed untreated MDS. We report detailed text and label statistics for all four datasets in Table 1.

LLM Performance

We report our prompts for each dataset and task in Table 2 and a detailed model performance evaluation in Table 3. Our primary performance metric, exact match accuracy, evaluates the ability of a model to correctly extract all fields for a report, using the labels of the first human annotator as "ground truth." We compare model accuracies to the accuracies of independent second human annotators using non-inferiority tests. We consider a model to have obtained "human-level performance" if it matches the accuracy of our second human annotator. Our second human annotators obtained exact match accuracies of 75.5 (95% CI 70.4, 80.3), 70.8 (95% CI 59.7, 80.6), 83.1 (95% CI 75.4, 88.5), 85.8 (95% CI 80.7, 89.9) in the breast, kidney, prostate, and MDS test set respectively. When leveraging dataset-specific fine-tuning, Llama-3.1 8B obtained exact-match accuracies of 91.5 (95% CI 88.1, 94.2), 72.2 (95% CI 61.1, 81.9), 91.5 (95% CI 85.4, 95.4), 89.4 (95% CI 84.9, 93.1) in the breast, kidney, prostate, and MDS test set respectively. This model obtained higher accuracies than the second human annotator in all four datasets, and this result was statistically non-inferior in the breast, prostate, kidney, and MDS test sets (p<0.001, p<0.001, p<0.01, p<0.001). These results are summarized in Figure 4, and we report additional detailed metrics by data field in Table 4. We report additional metrics, including precision, recall, and F1 scores, in the supplementary results.

Llama-3.1 8B and Mistral-0.3 7B obtained qualitatively similar results across fine-tuning settings, obtaining average exact match accuracies ranging from 82.8% to 86.2% compared to 78.8% by second human annotators. These results suggest that researchers can obtain human-level results if they annotate data for a single task (i.e.,

question-specific finetuning); alternatively, institutions can train a single model to support all tasks (i.e., mixed-dataset finetuning) to obtain human-level results. Dataset-specific finetuned Llama-3.1 8B and dataset-specific finetuned Mistral-0.3 7B significantly outperformed their zero-shot counterparts across all datasets (p<0.05). GPT-4, which received no fine-tuning, obtained human-level exact match accuracies in the breast, prostate, and MDS test sets (non-inferiority p<0.001). In the kidney test set, GPT-4 did not obtain non-inferior accuracy relative to the second human annotator (63.9% vs 70.8%, p=0.199).

Learning Curve Analysis and Hyperparameter Sensitivity

To understand the minimum number of training samples required to achieve human-level performance, we retrained our dataset-specific fine-tuned Llama-3.1 8B model with subsets of our training set (Figure 5). Across each test set, we report the performance of our second human annotator on our dotted line. Our fine-tuned Llama-3.1 8B matched human performance when leveraging only 100, 95, 43, and 72 training reports for the breast, kidney, prostate, and MDS test sets, respectively. Each dataset-level model took 1-3 hours to train using a single A40 GPU. At the time of writing, these experiments would cost between $0.80 to $2.40 on a private cloud. Next, we assessed the sensitivity of our models to the optimal choice of training hyper-parameters, including learning rate, number of training epochs, LoRa scaling (i.e., alpha), and LoRa rank (Figure 6). We find that our fine-tuning results are sensitive to the choice of learning rate; while leveraging a learning rate of 1e-4 obtains a dataset-average exact-match accuracy of 86.2%, learning rates of 1e-3 and 1e-5 obtain degraded accuracies of 4.7% and 79.4% respectively.

Discussion

We developed Strata, a lightweight open-source library for LLM-based clinical information extraction. Strata supports LLM prompt development, parameter-efficient fine-tuning, model evaluation, and deployment. Using Strata and minimal compute resources, namely a single commodity GPU (Nvidia A40) per experiment, we demonstrated that fine-tuned open-source LLMs achieve human-level performance in diverse, real-world clinical research applications across prostate MRI, breast pathology, kidney pathology, and myelodysplastic syndrome pathology reports. Our fine-tuned Llama-3.1 8B model was non-inferior to a second human annotator in all test sets. Moreover, Llama-3.1 8B demonstrated human performance leveraging only 100, 95, 43, and 72 training reports in our breast, kidney, prostate, and MDS test sets. These results demonstrate that fine-tuned LLMs offer a practical solution for clinical information extraction, requiring limited computational and human effort; our "low-code" open-source library is designed to democratize access to these tools.

Much of prior work on using LLMs for clinical information extraction has focused on commercial models such as ChatGPT (18). In our study, we found that GPT-4 demonstrated human-level zero-shot performance in three out of four test sets, namely breast, prostate, and MDS, and it was not non-inferior to our second annotator in the kidney dataset. Relying on commercial models to develop research databases poses several challenges. Using commercial models for protected health information requires institutional agreements to address privacy concerns, creating a significant access barrier. Moreover, rigorous research practices require reproducibility; as commercial LLMs are updated without user oversight, researchers cannot easily reproduce prior model queries or ensure consistent extraction quality. In contrast, our small open-source LLMs can be locally hosted, rigorously version-controlled, and easily customized for new applications.

We found that open-source LLMs address the limitations of traditional NLP techniques. Trivedi et al. (19) previously evaluated the performance of conventional NLP techniques applied to breast pathology reports and found that performance was lower for cases over 1024 characters with an F-measure of 0.83. In contrast, we saw consistent performance across our datasets, where all reports across all test sets contained over 1024 characters. Yala et al. (4) developed statistical machine learning tools for parsing breast pathology reports; while the tool achieved an exact-match accuracy of 90%, it required over 6000 annotations to reach this performance. In contrast, we demonstrated that we could achieve human-level results leveraging only ≤100 training set reports, addressing the primary limitation of this prior work.

Our study has limitations. We used datasets from two tertiary academic institutions, which may not account for variability in pathology report structures, terminology, and style across different institutions. Moreover, our study did not evaluate the ability of fine-tuned LLMs to generalize across institutions, and our clinical information extract tasks only capture a fraction of the data elements in clinical reports. Additional work is needed to broaden our results to more tasks and institutions.

In conclusion, our study shows that fine-tuned open-source LLMs can achieve human-level performance while leveraging modest annotation (i.e., ≤100 reports) and computational resources (i.e., <3.00$). Self-hosted open-source LLMs offer a compelling and high-performance alternative to commercial LLMs. We release Strata, our lightweight library, to broaden access to these tools.

Acknowledgements

We want to thank Trevor Darrell for thoughtful feedback on this study and Li-Ching Chen and Natalia Harguindeguy for beta-testing Strata. We also want to thank the UCSF Facility of Advanced Computing team, including Hunter McCallum, Sandeep Giri, Rhett Hillary, Marissa Jules, Sean Locke, and John Gallias, for their invaluable work in supporting our computational environment.

References

1. Yala A, Mikhael PG, Strand F, et al. Toward robust mammography-based models for breast cancer risk. Sci Transl Med. 2021;13(578):eaba4373. doi: 10.1126/scitranslmed.aba4373.
2. Gao S, Alawad M, Schaefferkoetter N, et al. Using case-level context to classify cancer pathology reports. Reddi HV, editor. PLOS ONE. 2020;15(5):e0232840. doi: 10.1371/journal.pone.0232840.
3. Alawad M, Gao S, Alamudun F, et al. Multimodal Data Representation with Deep Learning for Extracting Cancer Characteristics from Clinical Text. . https://www.osti.gov/biblio/1737476.
4. Yala A, Barzilay R, Salama L, et al. Using machine learning to parse breast pathology reports. Breast Cancer Res Treat. 2017;161(2):203–211. doi: 10.1007/s10549-016-4035-1.
5. Oleynik M, Patrão DFC, Finger M. Automated Classification of Semi-Structured Pathology Reports into. Stud Health Technol Inform. 2017;235:256-260. PMID: 28423793..
6. Kavuluru R. Automatic Extraction of ICD-O-3 Primary Sites from Cancer Pathology Reports. AMIA Jt Summits Transl Sci Proc. 2013 Mar 18;2013:112-6. PMID: 24303247; PMCID: PMC3845766.
7. Wieneke AE, Bowles EJA, Cronkite D, et al. Validation of natural language processing to extract breast cancer pathology procedures and results. J Pathol Inform. 2015;6(1):38. doi: 10.4103/2153-3539.159215.
8. Gertz RJ, Dratsch T, Bunck AC, et al. Potential of GPT-4 for Detecting Errors in Radiology Reports: Implications for Reporting Accuracy. Moy L, editor. Radiology. 2024;311(1):e232714. doi: 10.1148/radiol.232714.
9. Doshi R, Amin KS, Khosla P, Bajaj S, Chheang S, Forman HP. Quantitative Evaluation of Large Language Models to Streamline Radiology Report Impressions: A Multimodal Retrospective Analysis. Radiology. 2024;310(3):e231593. doi: 10.1148/radiol.231593.
10. Zhang L, Liu M, Wang L, et al. Constructing a Large Language Model to Generate Impressions from Findings in Radiology Reports. Moy L, editor. Radiology. 2024;312(3):e240885. doi: 10.1148/radiol.240885.
11. Bhayana R, Nanda B, Dehkharghanian T, et al. Large Language Models for Automated Synoptic Reports and Resectability Categorization in Pancreatic Cancer. Fowler K, editor. Radiology. 2024;311(3):e233117. doi: 10.1148/radiol.233117.
12. Dubey A, Jauhri A, Pandey A, et al. The Llama 3 Herd of Models. arXiv; 2024. http://arxiv.org/abs/2407.21783. Accessed October 8, 2024.
13. Touvron H, Lavril T, Izacard G, et al. LLaMA: Open and Efficient Foundation Language Models. arXiv; 2023. http://arxiv.org/abs/2302.13971. Accessed October 8, 2024.
14. Touvron H, Martin L, Stone K, et al. Llama 2: Open Foundation and Fine-Tuned Chat Models. arXiv; 2023. http://arxiv.org/abs/2307.09288. Accessed October 8, 2024.
15. Jiang AQ, Sablayrolles A, Mensch A, et al. Mistral 7B. arXiv; 2023. http://arxiv.org/abs/2310.06825. Accessed October 8, 2024.
16. Ouyang L, Wu J, Jiang X, et al. Training language models to follow instructions with human feedback. arXiv; 2022. http://arxiv.org/abs/2203.02155. Accessed October 8, 2024.
17. Hu EJ, Shen Y, Wallis P, et al. LoRA: Low-Rank Adaptation of Large Language Models. arXiv; 2021. http://arxiv.org/abs/2106.09685. Accessed October 8, 2024.
18. Le Guellec B, Lefèvre A, Geay C, et al. Performance of an Open-Source Large Language Model in Extracting Information from Free-Text Radiology Reports. Radiol Artif Intell. 2024;6(4):e230364. doi: 10.1148/ryai.230364.
19. Trivedi HM, Panahiazar M, Liang A, et al. Large Scale Semi-Automated Labeling of Routine Free-Text Clinical Records for Deep Learning. J Digit Imaging. 2019;32(1):30–37. doi: 10.1007/s10278-018-0105-8.
20. Breischneider C, Zillner S, Hammon M, Gass P, Sonntag D. Automatic Extraction of Breast

Cancer Information from Clinical Reports. 2017 IEEE 30th Int Symp Comput-Based Med Syst CBMS. Thessaloniki: IEEE; 2017. p. 213–218. doi: 10.1109/CBMS.2017.138.

21. Schroeck FR, Patterson OV, Alba PR, et al. Development of a Natural Language Processing Engine to Generate Bladder Cancer Pathology Data for Health Services Research. Urology. 2017;110:84–91. doi: 10.1016/j.urology.2017.07.056.

22. Nguyen AN, Moore J, O'Dwyer J, Philpot S. Automated Cancer Registry Notifications: Validation of a Medical Text Analytics System for Identifying Patients with Cancer from a State-Wide Pathology Repository. .

Tables

Table 1. Detailed Outcome and Text Characteristics for each Dataset

Outcome Characteristic	Train	Val	Test
Breast	n=391	n=293	n=294
No. of words mean±SD (min-max)	809±677 (200-3596)	733±579 (189-3991)	766 ± 640 (183-3717)
Anatomic Site			
Right breast	222 (57%)	162 (55%)	166 (56%)
Left breast	213 (54%)	158 (54%)	150 (51%)
Right lymph node	41 (10%)	30 (10%)	336 (114%)
Left lymph node	41 (10%)	29 (10%)	34 (12%)
Diagnosis			
Cancer	242 (62%)	177 (60%)	190 (65%)
High risk	31 (8%)	29 (10%)	23 (8%)
Benign	118 (30%)	87 (30%)	81 (28%)
Laterality-specific subtyping			
Ductal carcinoma in situ	142 (36%)	109 (37%)	121 (41%)
Invasive ductal carcinoma	109 (28%)	91 (31%)	109 (37%)
Invasive lobular carcinoma	25 (6%)	16 (5%)	12 (4%)
Adenocarcinoma NOS	12 (3%)	12 (4%)	5 (2%)
Kidney	n=95	n=71	n=72
No. of words mean±SD (min-max)	768±412 (270-3081)	741±361 (275-2081)	688±259 (128-1652)
Cancer Diagnosis			
Yes	84 (88%)	62 (87%)	68 (94%)
No	11 (12%)	9 (13%)	4 (6%)
Cancer Anatomic Site			
Left lower pole	19 (20%)	12 (17%)	11 (15%)
Right lower pole	10 (11%)	8 (11%)	11 (15%)
Left middle pole	11 (12%)	14 (20%)	11 (15%)
Right middle pole	17 (18%)	10 (14%)	15 (21%)
Left upper pole	17 (18%)	17 (24%)	16 (22%)
Right upper pole	13 (14%)	10 (14%)	13 (18%)
Prostate	n=172	n=129	n=130

No. of words mean±SD (min-max)	431±131 (110-916)	436±176 (166-1587)	423±109 (172-699)
PIRADS			
5	58 (34%)	32 (25%)	43 (33%)
4	69 (40%)	54 (42%)	46 (35%)
3	15 (9%)	18 (14%)	20 (15%)
2	14 (8%)	12 (9%)	12 (9%)
1	3 (2%)	2 (2%)	0 (0%)
Cancer Diagnosis			
Yes	149 (87%)	108 (84%)	111 (85%)
No	23 (13%)	21 (16%)	19 (15%)
MDS	n=289	n=217	n=218
No. of words mean ± SD (min-max)	810±222 (219-1652)	805±234 (171-1725)	785±225 (151-1612)
Bone marrow			
Yes	254 (88%)	195 (90%)	193 (89%)
No	35 (12%)	22 (10%)	25 (11%)
Untreated Myelodysplastic Syndrome			
Yes	19 (7%)	18 (8%)	16 (7%)
No	235 (81%)	177 (82%)	177 (81%)
Missing	35 (12%)	22 (10%)	25 (12%)

Note – Unless otherwise specified, data are numbers of reports, with percentages for each split in parentheses. For breast and prostate, "laterality-specific" means that the model was asked separately for each laterality (see Table 2). For diagnosis characteristics, the outcomes sum to 100%. For anatomic site and subtyping, the outcomes are not mutually exclusive, so the outcomes sum to >100%. NOS = not otherwise specified.

Table 2. Task-specific LLM Prompts for each Dataset

Breast	
Anatomic Site	What are the tissue sources that are investigated in this report? Your answer can include "left breast", "right breast", "left lymph node", or "right lymph node" if there are additional sources. If multiple sources are present, list all of them and separate them with a comma. Do not provide explanations. Do not output anything other than the four choices.
Diagnosis	Is there cancer diagnosed in this report? If so, what is the laterality of the cancer? Your answer should be in json format: {"left": __, "right": __}, where each blank is filled in by "1" if any cancer is deterministically diagnosed (i.e. DCIS, IDC, ILC, other invasive tumors, adenocarcinoma), "0" if the tissue is benign, or "2" if there are no cancers but high risk lesions identified explicitly. High risk lesions are defined as any of the following: atypia, radial scar, complex sclerosing lesion, atypical ductal hyperplasia, lobular carcinoma in situ, atypical lobular hyperplasia, FEA, ALH, ADH, phyllodes. If no breast or axillary lymph node is examined for a laterality, or if the report is about other organs (e.g. ovaries, liver, bone, adnexa, omentum, or lymph nodes in the abdomen/pelvis), fill in the corresponding blanks with "N/A". Provide your answer in the required format. Do not provide explanations or output anything else.
Laterality specific subtyping (left)	Identify which laterality of tissues are examined in this report. If the left breast is not examined in this report, output "N/A" and stop generating immediately, ignore the following prompts. Proceed to answer the following question only if the left breast is examined: Based only on the part of the report that is about the left breast, are the following type(s) of cancer diagnosed in the left breast? Possible diagnoses include: "DCIS" for ductal carcinoma in situ, "IDC" for invasive ductal carcinoma, "ILC" for invasive lobular carcinoma, or "adenocarcinoma" for adenocarcinoma. Provide your answer in json format: {"DCIS": __, "IDC": __, "ILC": __, "adenocarcinoma": __} Fill in the corresponding blank with 0 if no such cancer is diagnosed, 1 if such cancer is diagnosed in the left breast. Provide your answer in the given json format. Do not provide explanations. Do not include information about the right breast.
Laterality specific subtyping (right)	Identify which laterality of tissues are examined in this report. If the right breast is not examined in this report, output "N/A" and stop generating immediately, ignore the following prompts. Proceed to answer the following question only if the right breast is examined: Based only on the part of the report that is about the right breast, are the following type(s) of cancer diagnosed in the right breast? Possible diagnoses include: "DCIS" for ductal carcinoma in situ, "IDC" for invasive ductal carcinoma, "ILC" for invasive lobular carcinoma, or "adenocarcinoma" for adenocarcinoma. Provide your answer in json format: {"DCIS": __, "IDC": __, "ILC": __, "adenocarcinoma": __} Fill in the corresponding blank with 0 if no such cancer is diagnosed, 1 if such cancer is diagnosed in the right breast. Provide your answer in the given json format. Do not provide explanations. Do not include information about the left breast.
Kidney	
Cancer Diagnosis	Based on information on the report, is there cancer diagnosed in the kidney? If this is not a kidney pathology report, answer 'no'. If the cancer is diagnosed in other organs outside of the kidney, answer 'no'. Possible cancer types include but is not limited to: renal cell carcinoma, collecting duct carcinoma, oncocytoma, and renal medullary carcinoma. Keep in mind that angiomyolipoma is not a cancer. Choose your answer from 'yes' or 'no'. Provide your answer as one word only, do not provide explanations.

Cancer Anatomic Site	Where in the kidney is the cancer located based on this report, if any? If there is no cancer diagnosed in the kidney, answer 'N/A' and stop generating. Choose your answer from 'left lower pole', 'right lower pole', 'left middle pole', 'right middle pole', 'left upper pole', 'right upper pole', 'not specified' or 'other'. If multiple cancer sites are present, list all of them and separate them with a comma. If the cancer is throughout the kidney, or if it replaces the kidney, answer all three poles of the laterality being examined. If the report does not identify in which pole the cancer is found, or if it says 'multifocal', answer 'not specified'. If the cancer is metastatic and there is no location specified inside the kidney, answer 'other'. If the cancer penetrates into other sites including ureter, renal sinus, renal vein, veins, hilum, lymphatics, adrenal gland, capsule/perirenal fat, add 'other' to your answer, in addition to the cancer site inside kidney. 'Superior pole' is synonymous to 'upper pole', 'inferior pole' is synonymous to 'lower pole'. Format your answer as one or more of these eight options only. Do not provide explanations.
Prostate	
PIRADS	Tell me the maximum PI-RADS Score of all the lesions in this report. For example, if there are three lesions with PI-RADS scores of 5, 4, and 4, then you should return "5". If there is only one lesion, return the PI-RADS score of that lesion. If there are both v1 and v2 PI-RADS scores reported, return the v2 scores. Return your answer as a JSON with the field name "overall_pirads_score". If you cannot find the data, return "NA" in the field. Format the field as type character. Do not include units with values, and make all letters lowercase.
Laterality specific cancer (left)	Is there a lesion or cancer present in the left side of the prostate? Return your answer as "1" for "yes" or "0" for "no" in JSON format with the field name "lesion_left_side". If you cannot find the data, return "NA" in the field. Format the field as type character. Do not include units with values, and make all letters lowercase.
Laterality specific cancer (right)	Is there a lesion or cancer present in the right side of the prostate? Return your answer as "1" for "yes" or "0" for "no" in JSON format with the field name "lesion_right_side". If you cannot find the data, return "NA" in the field. Format the field as type character. Do not include units with values, and make all letters lowercase.
MDS	
Bone marrow	Is the following pathology report from a bone marrow biopsy rather than a FLT3 DNA report, cytogenics report, or FISH report? Please ONLY answer either "yes" or "no". Do not provide explanations.
Untreated Myelodysplastic Syndrome	Is the biopsy usable? Please ONLY answer either "yes" or "no". A sample is usable if the pathology report notes MDS is present, if the biopsy is not from an outside center or by referral, if the patient has not been pretreated, if the patient does not have AML, MPN, myelofibrosis, essential thrombocythemia, thrombocytosis, polycythemia vera, chronic myelomonocytic leukemia (CMML), or any other clonal neoplasm. Do not provide explanations or output anything else.

Note – DCIS = ductal carcinoma in situ, IDC = invasive ductal carcinoma, ILC = invasive lobular carcinoma, FEA = flat epithelial hyperplasia, ALH = atypical lobular hyperplasia, ADH = atypical ductal hyperplasia, PI-RADS = Prostate Imaging-Reporting and Data System, FLT3 = FMS-like tyrosine kinase 3, FISH = fluorescence in situ hybridization, AML = acute myeloid leukemia, MPN = myeloproliferative neoplasms.

Table 3. Dataset-Level Exact Match Accuracies for the Second Human Annotator, GPT-4 and Open-source LLMs.

Dataset	Second human annotator	Closed-source zero shot — GPT-4	Open-source zero-shot Llama-3.1 8B	Open-source zero-shot Mistral-v0.3 7B	Question-specific fine-tuning Llama-3.1 8B	Question-specific fine-tuning Mistral-v0.3 7B	Dataset-specific fine-tuning Llama-3.1 8B	Dataset-specific fine-tuning Mistral-v0.3 7B	Mixed-dataset fine-tuning Llama-3.1 8B	Mixed-dataset fine-tuning Mistral-v0.3 7B
Breast	75.5 [70.4, 80.3]	84.0 [79.6, 87.8]	42.9 [37.4, 48.6]	29.3 [24.1, 34.7]	89.1 [85.0, 92.2]	91.5 [87.8, 94.2]	91.5 [88.1, 94.2]	**92.2 [88.8, 94.9]**	93.5 [90.1, 95.9]	90.1 [86.4, 93.2]
Kidney	70.8 [59.7, 80.6]	63.9 [51.4, 73.6]	55.6 [43.1, 66.7]	54.2 [41.7, 65.3]	70.8 [59.7, 80.6]	66.7 [55.6, 76.4]	**72.2 [61.1, 81.9]**	68.1 [56.9, 77.8]	70.8 [59.7, 80.6]	75.0 [63.9, 83.3]
Prostate	83.1 [75.4, 88.5]	**93.1 [87.7, 96.9]**	28.5 [20.8, 36.9]	76.9 [68.5, 83.8]	90.8 [84.6, 94.6]	87.7 [80.8, 92.3]	91.5 [85.4, 95.4]	91.5 [85.4, 95.4]	93.8 [88.5, 96.9]	91.5 [85.4, 95.4]
MDS	85.8 [80.7, 89.9]	86.7 [82.1, 90.8]	76.6 [70.6, 81.7]	16.1 [11.5, 21.6]	86.7 [81.7, 90.8]	85.3 [80.3, 89.4]	**89.4 [84.9, 93.1]**	77.5 [71.6, 82.6]	89.4 [84.9, 93.1]	84.4 [79.4, 89.0]
Average across all datasets	78.8 ±6.9	81.9 ±12.6	50.9 ±20.4	27.7 ±19.6	84.4 ±9.2	82.8 ±11	86.2 ±9.4	82.3 ±11.7	85 ±9.6	82.8 ±10

Note – Dataset-level exact match accuracies are followed by 95% confidence intervals in brackets. This metric evaluates the ability of each model to correctly extract all components from a report correctly. We report the average exact match accuracy across all four datasets, in addition to standard deviation, in the "Average across all datasets" row.

Table 4. Detailed comparison of fine-tuned Llama 3.1 to Second Human Annotator

	Dataset-specific Fine-tuned Llama 3.1 8B	Second human annotator	Non-inferiority p-values
Breast			
Anatomic Site	99.0 [97.3, 99.7]	87.8 [84.0, 91.2]	
Diagnosis	95.6 [92.9, 97.6]	92.9 [89.5, 95.2]	
Laterality-specific subtyping (left)	99.3 [97.6, 100.0]	94.2 [91.2, 96.3]	
Laterality-specific subtyping (right)	96.6 [93.9, 98.3]	95.2 [92.5, 97.3]	
Overall exact match	91.5 [87.8, 94.2]	75.5 [70.1, 80.3]	< 0.001
Kidney			
Cancer Diagnosis	97.2 [90.3, 100.0]	93.1 [84.7, 97.2]	
Cancer Anatomic Site	73.6 [62.5, 83.3]	70.8 [59.7, 80.6]	
Overall exact match	72.2 [61.1, 81.9]	70.8 [59.7, 80.6]	0.008
Prostate			
PIRADS	97.7 [93.8, 99.2]	91.5 [85.4, 95.4]	
Cancer (left)	96.2 [91.5, 98.5]	93.1 [87.7, 96.9]	
Cancer (right)	96.2 [91.5, 98.5]	95.4 [90.8, 98.5]	
Overall exact match	91.5 [85.4, 95.4]	83.1 [76.2, 88.5]	< 0.001
MDS			
Bone marrow	91.7 [87.6, 95.0]	92.7 [88.5, 95.9]	
Untreated Myelodysplastic Syndrome	96.9 [93.3, 99.0]	92.2 [87.6, 95.3]	
Overall exact match	89.4 [84.9, 93.1]	85.8 [80.3, 89.9]	< 0.001

Note – Data are exact match accuracies with 95% confidence intervals in brackets. Overall exact match accuracy measures if exactions across all tasks for a particular report were correct. The p-values are calculated with non-inferiority margins based on the size of each test set, 80% power, and a significance threshold of 0.05. This resulted in non-inferiority margins of 6.3%, 13.5%, 8.2%, and 5.9% for breast, kidney, prostate, and MDS, respectively.

Figure Legends

Figure 1. Dataset construction flowchart for our breast(a), kidney(b), prostate(c), and MDS (d) datasets. UCSF = University of California, San Francisco, VUMC = Vanderbilt University Medical Center, EHR = electronic health records, MDS = Myelodysplastic Syndrome.

Figure 2. Process for leveraging open-source LLMs to extract structured information from clinical reports. The input to the LLM consists of a user prompt, which specifies the task (e.g., cancer subtyping), paired with the report text. An open-source LLM contains pre-trained weights (e.g., 8B parameters for Lamma-3.1 8B) learned across web-scale datasets; when fine-tuning an LLM, we introduce additional LoRA weights (~400M parameters) to customize the model. The model generates an answer in text, parsed by a user-defined "parse function" into a tabular form.

Figure 3. Process of using Strata to create research databases. The researcher labels a subset of the reports, defines prompts, and creates parsing functions to interpret the model's response. Given this information, Strata supports LLM fine-tuning and deployment. In LoRA fine-tuning, the model's LoRA weights are trained to generate the templated answers. Strata supports model evaluation and efficient bulk-inference. Bulk-inference is used to create a research database from all unlabeled reports at the institution.

Figure 4. Summarized dataset-level results. Bar graph shows exact match accuracy for each dataset. Selected models include the second human annotator, zero-shot GPT-4, and fine-tuned and zero-shot Llama 3.1 8B. The human, snowflake, and flame icons represent the human, zero-shot, and fine-tuned models respectively.

Figure 5. Learning curves analysis across all four datasets. Blue line graphs show the exact match accuracy for dataset-specific finetuned Llama 3.1 when leveraging 0%, 25%, 50%, and 100% of the training data. The dotted line displays the performance of the second human annotator. The stars show the number of reports used to match performance of the second human annotator.

Figure 6. Hyperparameter sensitivity analysis for mixed-dataset fine-tuned Llama 3.1 8B. Heat maps display the average dataset-level exact match accuracy across datasets, across a range of values for each hyper-parameter. Llama 3.1 is robust to the choice of training epochs, LoRA (low-rank adaptation) scaling, and LoRA rank, but the choice of learning rate can significantly alter performance.

Figure 1. Dataset construction flowchart for our breast(a), kidney(b), prostate(c), and MDS (d) datasets. EHR = electronic health records, MDS = Myelodysplastic Syndrome.

Figure 2. Process for leveraging open-source LLMs to extract structured information from clinical reports. The input to the LLM consists of a user prompt, which specifies the task (e.g., cancer subtyping), paired with the report text. An open-source LLM contains pre-trained weights (e.g., 8B parameters for Lamma-3.1 8B) learned across web-scale datasets; when fine-tuning an LLM, we introduce additional LoRA weights (~400M parameters) to customize the model. The model generates an answer in text, parsed by a user-defined "parse function" into a tabular form.

Figure 3. Process of using Strata to create research databases. The researcher labels a subset of the reports, defines prompts, and creates parsing functions to interpret the model's response. Given this information, Strata supports LLM fine-tuning and deployment. In LoRA fine-tuning, the model's LoRA weights are trained to generate the templated answers. Strata supports model evaluation and efficient bulk-inference. Bulk-inference is used to create a research database from all unlabeled reports at the institution.

Figure 4. Summarized dataset-level results. Bar graph shows exact match accuracy for each dataset. Selected models include the second human annotator, zero-shot GPT-4, and fine-tuned and zero-shot Llama 3.1 8B. The human, snowflake, and flame icons represent the human, zero-shot, and fine-tuned models respectively.

Figure 5. Learning curves analysis across all four datasets. Blue line graphs show the exact match accuracy for dataset-specific finetuned Llama 3.1 when leveraging 0%, 25%, 50%, and 100% of the training data. The dotted line displays the performance of the second human annotator. The stars show the number of reports used to match performance of the second human annotator.

Figure 6. Hyperparameter sensitivity analysis for mixed-dataset fine-tuned Llama 3.1 8B. Heat maps display the average dataset-level exact match accuracy across datasets, across a range of values for each hyper-parameter. Llama 3.1 is robust to the choice of training epochs, LoRA (low-rank adaptation) scaling, and LoRA rank, but the choice of learning rate can significantly alter performance.